A groundbreaking ceremony took place last week.
Four new production lines are to be built, which, among other things, will produce mRNA vaccines for customers. As previously announced, part of the new capacity will be available to the German federal government as and when required as part of its pandemic preparedness contracts.
Melanie Käsmarker, managing director of Wacker Biotech Halle, said there are opportunities mRNA actives in and beyond vaccines. “We see a lot of potential here and going forward want to serve the increasing demand for mRNA actives from Halle.”
The construction of the mRNA competence center will more than triple Wacker’s production capacity at the Halle site. The new building will be completed and the production lines operational in less than 24 months, reported the company.
Alongside the four mRNA production lines, the new building will also contain storage areas and quality control laboratories, as well as office space and recreation rooms.
Wacker said it intends to hire around 200 new employees as part of the expansion, with it looking to hire laboratory assistants and pharmaceutical technicians, as well as employees in production, supply chain management and quality control. They will be trained up in the coming months to be ready for the start of production in 2024, said the developer.
Exyte has been hired as general contractor for the construction and validation of the new facilities. That group specializes in the delivery of semiconductor and pharma plants and is considered a pioneer in cleanroom technology, said the contract manufacturer.
"triple" - Google News
July 11, 2022 at 07:47PM
https://ift.tt/EtBrDL1
Expansion to triple production capacity at Wacker mRNA site in Germany - BioPharma-Reporter.com
"triple" - Google News
https://ift.tt/bwtvW2g
https://ift.tt/MClemq6
Bagikan Berita Ini
0 Response to "Expansion to triple production capacity at Wacker mRNA site in Germany - BioPharma-Reporter.com"
Post a Comment